Search Site

Jason D. Wright, MD

  • Sol Goldman Associate Professor of Gynecologic Oncology (in Obstetrics and Gynecology)
  • Chief, Division of Gynecologic Oncology

This provider accepts new patients

Jason D. Wright, MD

Dr. Wright completed residency and a fellowship in Gynecologic Oncology at Washington University in St. Louis. He is board certified in Obstetrics and Gynecology and Gynecologic Oncology. Dr. Wright sees women with all gynecologic cancers and has extensive training in minimally invasive surgery, extended pelvic resections, and pelvic reconstructive surgery. Dr. Wright also cares for a large number of women with hereditary cancer syndromes. In addition, Dr. Wright sees women with who require complex gynecologic procedures as well as women with placenta accreta.

Dr. Wright is a nationally recognized expert in the treatment of gynecologic cancers and gynecologic surgery. He has authored over 300 articles, chapters, and textbooks. A major focus of Dr. Wright's work is the delivery of quality care to women with cancer and the improvement of outcomes of women with cancer and those who undergo surgery. Dr. Wright's primary clinical research focuses on the evaluation of novel therapeutics, targeted therapies and biologic treatments for women with gynecologic cancers. Dr. Wright is the principal investigator on a number of clinical trials. Dr. Wright is a member of the Alpha Omega Alpha (AOA) Honor Society, a full member of the Society of Gynecologic Oncology, the American Society of Clinical Oncology and a Fellow of the American College of Obstetricians and Gynecologists. Dr. Wright has won numerous teaching and research awards and lectures throughout the United States and internationally.

Board Certifications

  • Gynecologic Oncology
  • Obstetrics and Gynecology

Areas of Expertise

  • Gynecologic Cancers
  • Cancer Care
  • Ovarian Cancer Genetic Susceptibility
  • Ovarian Cancer
  • Minimally Invasive Gynecologic Surgery
  • Laparoscopic Gynecologic Surgery
  • Gynecologic Cancer
  • Cervical Cancer
  • Uterine Cancer

Education & Training

  • University of Missouri, Kansas City
  • Internship: Barnes Jewish Hospital-Washington University School of Medicine
  • Residency: Barnes Jewish Hospital-Washington University School of Medicine
  • Fellowship: Barnes Jewish Hospital-Washington University School of Medicine

Locations

  • Herbert Irving Pavilion

    161 Fort Washington Avenue
    Floor: 8
    New York, NY 10032
    Phone:
    (212) 305-3410
    For new and current patient appointments, call:
    (212) 305-3410

NIH Grants

  • A SINGLE ARE, OPEN LABEL, PHASE IIB STUDY TO ASSESS THE EFFICACY AND SAFETY OF THE COMBINATION CEDIRANIB AND OLAPARIB TABLETS IN WOMEN WITH RECURRENT PLATINUM RESISTANT EPITHELIAL OVARIAN CANCER, INCLUDING FALLOPIAN (P&S Industry Clinical Trial)

    Mar 7 2018 - Mar 7 2023

    A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IVOVARIAN, FALLOPIAN TUBE, (P&S Industry Clinical Trial)

    Sep 7 2017 - Sep 7 2022

    A BLINDED PROSPECTIVE STUDY OF THE PERFORMANCE OF HE4 TO PREDICT RECURRENCE IN PATIENTS WITH ADVANCED OVARIAN CANCER, PERITONEAL CARCINOMA AND TUBAL CARCINOMA (P&S Industry Clinical Trial)

    Oct 28 2014 - Oct 28 2019

    A MULTICENTER PROSPECTIVE STUDY OF CA 125 AND HE4 SERUM BIOMARKERS FOR MONITORING THE RESPONSE TO FIRST-LINE THERAPY IN WOMEN WITH PRIMARY EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCERS (P&S Industry Clinical Trial)

    Oct 28 2014 - Oct 28 2019

    COMORBIDITY, TOXICITY AND BREAST CANCER SURVIVAL AMONG WOMEN ON AND OFF CLINICAL TRIALS (Private)

    Aug 2 2016 - Aug 1 2019

    USING SWOG-MEDICARE DATABASE TO EVALUATE LONG-TERM TOXICITIES OF CANCER SURVIVORS (Federal Gov)

    Feb 15 2013 - Jan 31 2018

    BREAST CANCER ACCESS TO CARE AND DISPARITIES RESEARCH PROGRAM (Private)

    Jan 1 2017 - Dec 31 2017

    THE INFLUENCE OF HOSPITAL VARIABILITY ON THE MANAGEMENT OF CANCER-ASSOCIATED COMPLICATIONS (Federal Gov)

    Jan 1 2013 - Dec 31 2017

    H3E US-X073 (P&S Industry Clinical Trial)

    Nov 28 2011 - Nov 28 2016

    MORAB-003-004 (P&S Industry Clinical Trial)

    Nov 23 2011 - Nov 23 2016

    A PHASE 3 PLACEBEO-CONTROLLED STUDY OF CARBOPLATIN/PACLITAXEL WITH OF WITHOUT CONCURRENT AND CONTINUATION MAINTENANCE (Private)

    Oct 8 2015 - Oct 7 2016

    HIPPOCOMPAL AND COGNITIVE FUNCTION, EXERCISE, AND OVARIAN CANCER: A PILOT STUDY (Federal Gov)

    Aug 1 2014 - Jul 31 2016

    INFLUENCE OF GEOGRAPHIC VARIATION ON ACCESS TO MINIMALLY INVASIVE GYNECOLOGIC CANCER SURGERY (Private)

    Jul 1 2015 - Jun 30 2016

    MCH RESEARCH (Federal Gov)

    Apr 1 2015 - Mar 31 2016

    PHASE II EVALUATION OF CARBOPLATIN,PACLITAXEL AND BEVACIZUMANEOADJUVANT THERAPY FOR EPITHELIAL OVARIAN (P&S Industry Clinical Trial)

    May 20 2010 - May 20 2015

    ONCOFISH CERVICAL TEST FOR DETECTION OF 3Q26 REGION GAIN (P&S Industry Clinical Trial)

    Jun 8 2009 - Dec 31 2014

    THERAPEUTIC TARGETING OF NOTCH IN OVARIAN CANCER (Federal Gov)

    Jul 1 2009 - Jul 31 2013

    ACCEPTANCE OF HUMAN PAPILLOMAVIRUS VACCINATION IN POSTPARTUMWOMEN (P&S Industry Clinical Trial)

    May 30 2009 - May 30 2012